From Fin Review - The study is continuing. FDA told MSB not to worry about recruiting the additional candidates, complete the study and have no issues with safety. See below:
"Biotech Mesoblast says its COVID-19 trial is not likely to meet its 30-day mortality reduction endpoint after a data readout of the trial's first 180 patients. It will complete the trial which is looking into a treatment for hospitalised COVID-19 ventilator dependent patients, as it has not yet accrued data on secondary endpoints. The US Data Safety Monitoring Board also effectively advised Mesoblast to finish the trial and recruit no further patients, although it said there were no issues with safety."
Ann: Mesoblast Update on COVID-19 ARDS Trial, page-234
-
- There are more pages in this discussion • 842 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.17 |
Change
-0.025(2.10%) |
Mkt cap ! $1.330B | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.22 | $1.15 | $6.344M | 5.404M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8683 | $1.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.17 | 32999 | 1 |
View Market Depth
| Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |